The Chairman & CEO of CASI Pharmaceuticals (NASDAQ: CASI) is Buying Shares

By Carrie Williams

Today, the Chairman & CEO of CASI Pharmaceuticals (CASIResearch Report), Wei-Wu He, bought shares of CASI for $1.07M.

This recent transaction increases Wei-Wu He’s holding in the company by 7.21% to a total of $18.2 million.

See today’s analyst top recommended stocks >>

Based on CASI Pharmaceuticals’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $1.34 million and GAAP net loss of -$12,899,000. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $9.26 million. Currently, CASI Pharmaceuticals has an average volume of 250.37K. The company has a one-year high of $3.82 and a one-year low of $1.15.

Starting in April 2019, CASI received 5 Buy ratings in a row.

Wei-Wu He’s trades have generated a 42.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.